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PERIOPERATIVE RISK IN PATIENTS WITH CLOVES SYNDROME 
 
JANELLE K. MCNEIL 
ABSTRACT 
Objective: CLOVES syndrome (CLO: congenital lipomatous overgrowth, V: vascular 
anomalies E: epidermal nevi S: spinal anomalies) is a rare, non-heritable sporadic 
overgrowth disorder with serious morbidity. Previous anecdotal reports indicate that 
CLOVES patients are at risk for serious thromboembolic events in the perioperative 
period. The purpose of this study is to systematically determine the adverse events 
associated with anesthesia and diagnostic or interventional procedures for CLOVES 
patients, so appropriate assessment of risk can be performed and adequate precautions 
can be taken in the future to prevent complications.  
Methods: We selected our study cohort by gathering patients in the Vascular Anomalies 
Center (VAC) database with the diagnosis of CLOVES syndrome. Our primary group of 
interest was patients that were anesthetized at Boston Children’s Hospital (BCH) since 
2005. All patients having the diagnosis of CLOVES were included. IRB approval was 
obtained prior to patient selection. Data was collected from BCH electronic medical 
records. Patient age, gender, ASA level, estimated amount of blood loss (EBL), surgery 
status, MRI status, complication(s), type of complication if any, and medical history was 
recorded in a Microsoft Excel document on a password-protected computer. Data 
analysis was carried out with no statistical analysis beyond simple incidence and 
prevalence of certain characteristics due to the extremely small patient population.  
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Results: We found that out of the 38 patients in our cohort, 15 (or 39%) suffered from 
complications during the perioperative period. A total of 23 (or 61%) did not have any 
complications. Results further showed that pulmonary emboli, respiratory issues, and 
hypo/hypertension were the most prevalent complications. In addition we found that there 
was no correlation between substantial EBL and complication occurrence in this cohort.   
Conclusion: In comparison to preliminary studies of Alomari, 2008 and Sapp et al., 
2007, we report a lower occurrence of thromboembolic events in CLOVES patients. We 
hypothesize that this is because patients at BCH were treated aggressively with various 
prophylactic methods to help minimize the risk of such events. We recommend that early 
prophylactic anticoagulation methods are applied to future patients. Additionally, we 
recommend that CLOVES patients be followed by a hematologist and care team that are 
familiar with the condition throughout their stay at the hospital to reduce the risk of 
thromboembolic events.   
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INTRODUCTION 
GENERAL BACKGROUND AND SIGNIFICANCE 
 
CLOVES syndrome is a newly delineated condition described as a sporadic non-
heritable overgrowth syndrome. The trademark features combine to form the acronym 
CLOVES; Congenital Lipomatous Overgrowth (CLO), Vascular anomalies (V), 
Epidermal nevi (E), Scoliosis/Spinal/Skeletal deformities (S) (Alomari, 2009). While 
hallmark features of this syndrome are included in the acronym, several other findings 
exist in different body systems and organs. Historically many patients with skeletal 
overgrowth were grouped as having Proteus syndrome (PS) and those with vascular 
anomalies were termed as having Klippel-Trenaunay syndrome (KTS) (Upton & Bloom, 
2013). Birth prevalence for KTS is 1 in 100,000 while birth prevalence for PS is 1 in 1 
million and CLOVES is more rare (Higurashi et al., 1990). Life expectancy for these 
patients is currently unknown, due to the disease being very new and rare.  
Patients with CLOVES syndrome will have many surgical procedures done to 
help treat and correct associated anomalies. With any surgery complications may arise 
and a serious complication reported in CLOVES patients is blood clots, also known as 
thrombi. The vascular malformations in CLOVES allow for slow or stagnant blood flow 
in malformed vessels, leading to disruption in the patient’s coagulation homeostasis and 
an increased risk of blood clots (Alomari, 2009). These clots may travel throughout the 
patient’s body and become lodged within the pulmonary vasculature as pulmonary 
emboli resulting in symptoms ranging from respiratory distress to loss of circulation and 
possibly death. Published studies report that pulmonary emboli are known to occur as a 
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complication of CLOVES in the perioperative period (Alomari, 2009). It is of particular 
importance to evaluate the incidence of such complications in the perioperative period in 
hopes of better determining prophylactic treatment. I hypothesize that the majority of 
perioperative complications seen in this patient population will be due to pulmonary 
emboli. 
No larger-scale examination of anesthetic considerations or periprocedure risk has 
been published for this highly rare and complex patient population. Boston Children’s 
Hospital (BCH) due to the credits of the Vascular Anomalies Center (VAC) cares for one 
of the largest groups of CLOVES patients in the world, thus making this institution the 
logical place to perform such a study. Slightly over 100 patients carry CLOVES 
diagnosis worldwide and approximately a third of them have been operated on at BCH.  
 
CLINICAL PHENOTYPES 
Diagnosis of CLOVES is based on clinical examination and imaging findings. 
Key phenotypic features can be identified prenatally, however upon birth, deformities are 
clearly present and recognized. Patients are phenotypically unique from one another, 
commonly expressing variable forms of limb and truncal anomalies (Upton & Bloom, 
2013). Such anomalies classically include; 1)- Lipomatous, (fatty tissue) growths. 2)-
Vasculature anomalies, specifically the veins become enlarged, such vessels are often 
referred to as ectatic. Capillaries, arteries, and lymphatic vessels can also be 
compromised by malformations. 3)- Overgrowth of the skeletal system and deformity of 
the extremities are present.  
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Truncal overgrowth  
 
The lipomatous masses that are associated with this disorder are usually 
accompanied by capillary malformations (CMs) and lymphatic malformations (LMs) in 
the truncal region and extremities (Figure 1A). Additionally in the extremities such 
masses may be present with or without skeletal overgrowth (Upton & Bloom, 2013). 
Lipomatous masses vary in size and in the area that is compromised from patient to 
patient. These fatty masses can be found in the cervical and gluteal areas, often extending 
into the abdominal wall (Alomari, 2009). Deeper extensions of the fatty masses may 
involve the retro-peritoneum, peritoneum, mediastinum, pelvis, and pleural spaces 
(Alomari, 2009). However, masses involving the trunk are predominately noted (Figure 
1C). Lipomatous overgrowths are unilateral or bilateral, meaning the masses may occur 
on one side of the body or on both sides. Additionally some patients report to have pain 
related to the mass (Alomari 2009).  
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Figure 1 Lipomatous Overgrowth. A: The patient has one massive lipomatous mass 
with an overlying port wine stain and one smaller fatty mass both in the truncal region. 
C: One large mid-truncal mass. Images taken from (Alomari, 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vasculature anomalies  
 
 As the infant progresses into childhood deeper fast-flow and slow-flow vascular 
anomalies become evident (Alomari, 2009).  Slow flow malformations may be composed 
of lymphatic, venous, and capillary lesions. Capillary malformations will be discussed 
under the cutaneous section. Lymphatic malformations vary in size and are typically 
associated with fatty overgrowth that is seen in CLOVES. The two major types of LMs 
are macrocystic and microcystic (Alomari & Dubois, 2011) (Figure 2 & Figure 3C). 
These lymphatic lesions are fluid filled channels or spaces (cysts) affecting mainly the 
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truncal and head/neck areas, although larger LMs may extend into the abdominal and 
thoracic cavities (Figure 3A). Small superficial lesions on the skin are usually prone to 
leakage, bleeding, and infection, however these smaller lesions are usually of minor 
clinical significance. Larger lesions can be physically deforming triggering decreased 
range of motion in these patients as well as infections (Alomari et al., 2010).  
 
Figure 2 Spinal Lymphatic Malformation. MRI image of left truncal mass showing 
microcystic and macrocystic LM (Blue arrows). Image taken from (Upton & Bloom 
2013).  
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Figure 3 Large Lymphatic Malformation. A: Large LM of the right neck C: Image 
exhibits macrocystic component of LMs.  Images taken from (Alomari & Dubois, 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Venous ectasia seen in CLOVES patients affects the upper/lower extremities and 
truncal area (Figure 4A). Some of the typical veins that are affected include the 
superior/inferior vena cava, subclavian, axillary, intercostal, innominate, and jugular 
veins (Alomari et al., 2010) (Figure 4B). Ectatic veins cause the blood to flow more 
slowly through these regions, which can increase the risk of clot formation and 
pulmonary embolism (PE), a major complication leading to possible death. The 
complexity of the vascular malformations (VMs) seen in CLOVES patients may be 
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associated with an increased or decreased incidence of PE’s, with more compromised 
vessels being more closely associated with PE’s and least compromised being less 
associated.  
In many patients the cause of a PE event cannot be identified, however in the 
study of Alomari et al., 2010 researchers estimated that in patients with upper extremity 
deep venous thrombi (blood clots) causative agents such as vigorous exercise, trauma, 
and anatomic compression accounted for approximately 14% of all PE’s in the study 
cohort. CLOVES patients may also develop painful clots (thrombophlebitis) due to their 
VMs (Alomari et al., 2010). Extensive clotting within VMs can alter the patient’s 
coagulation system (blood clot system) leading to the need for medical therapy or 
frequent blood transfusions to maintain coagulation homeostasis.  
The fast flow lesions known as arteriovenous malformations (AVM) are rare in 
CLOVES patients. Within an AVM there is an abnormal connection between the arteries 
and veins creating a shortcut for blood to bypass the capillaries. High flow lesions 
typically occur in this syndrome adjacent to the spinal column, known as the paraspinal 
region and less often in the chest and extremities (Alomari et al., 2011). AVMs 
pathologically manifest in patients as pain, hyperemia (cutaneous redness), overgrowth, 
bleeding, and pulsatility (Alomari & Dubois, 2011).  
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Figure 4 Ectatic Veins. A: Large white arrow illustrating ectasia of the lower extremity. 
Image taken from (Alomari & Dubois 2011). B: Black arrows indicate the innominate 
vein that is markedly dilated. Image taken from (Alomari et al., 2010). 
 
 
Spinal/CNS 
 
The spinal cord in CLOVES patients can be affected in several different ways. 
Lipomatous masses near the spine may remain stable in size and cause no symptoms 
whereas others may grow and lead to neurologic injuries (Alomari et al., 2011). In the 
paravertebral region, fatty infiltration into vital structures may occur due to the presence 
of high flow vascular malformations  (Alomari et al., 2011). Fatty penetration in this 
region is commonly seen into the posterior mediastinum and can encompass the spinal 
cord/canal, initially compromising spinal cord vessels (Figure 5). With further 
penetration into the spinal canal, cord compression, tissue ischemia, and venous 
hypertension within the cord can result (Alomari et al., 2011). In addition to fatty 
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infiltration, dilated dural veins in the spinal canal can also become a problem leading to 
myelopathy and venous hypertension (Alomari et al., 2011).  
Scoliosis is another common finding in CLOVES patients; this anomaly tends to 
be progressive as the child ages (Alomari, 2008) (Figure 6). Researchers are unsure if 
scoliosis is a result of the paraspinal AVMs and fatty overgrowth or if this anomaly is a 
separate entity. Patients are at an increased risk of tethered spinal cord, which is when the 
spinal cord is abnormally attached to the tissues around the spine, most commonly seen at 
the base of the spine (Figure 7). This results in the inability of the spinal cord to move 
freely within the spinal canal, causing the nervous system to function abnormally 
(neurologic compromise) as the patient grows. Neural tube defects such as spina bifida 
are seen as well (Alomari et al., 2011). 
A few documented cases of CLOVES patients have presented with central 
nervous system (CNS) malformations. It is suggested that hemimegalencephaly, 
increased size of one hemisphere of the brain and agenesis of the corpus callosum, 
complete or partial absence of the interhemispheric connecting structures may be rare 
findings associated with CLOVES patients (Gucev et al., 2008) (Figure 8). Both of the 
above CNS malformations have been reported to manifest as seizures in CLOVES 
patients (Gucev et al., 2008). Altogether CNS malformations may in fact be more 
prevalent in CLOVES than initial reports (Alomari, 2008 & Sapp et al., 2007) suggested. 
Despite CNS malformations most CLOVES patients are intellectually normal.  
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Figure 5 Lipomatous Overgrowth in Spinal Region. MRI image demonstrates fatty 
mass (straight arrows) extending into the posterior mediastinum and paraspinal region 
(curved arrow). Scoliosis is also present. Image taken from (Kurek et al., 2012). 
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Figure 6 Different Degrees of Scoliosis. Image to the left indicates moderate scoliosis. 
The right image indicates mild scoliosis in the sacral region. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 Tethered Spinal Cord. Image taken from Medscape.com 
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Figure 8 CNS Malformations. CT scans shows encephalomalacia, enlarged ventricles 
hemimegalencephaly and partial agenesis of the corpus callosum. Image taken from 
(Guvev et al., 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Upper and lower extremities  
 
 Commonly found in CLOVES patients is length asymmetry of the upper and 
lower extremities. Diffuse overgrowth of the bones, muscles, nerves and fat can cause 
asymmetrical enlargement of the limbs.  Depending on the severity of the overgrowth(s) 
the patient’s limbs may be referred to as gigantic (Figure 9).  Adipose tissue is the most 
common type of overgrowth seen in patients (Upton & Bloom, 2013).  
Within the foot, common deformities include a large wide triangular foot, large 
metatarsal spaces, sandal gap toes, which are an increased space between the first and 
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second toe, and lipomatous masses that can occur on the dorsal and ventral surfaces of 
the feet (Figure 10B). Pathologies affecting the digits on the feet are macrodactyly, which 
is the enlargement of one or more digit typically involving the third toe (Figure 10A). 
Polydactyly, is when there are more than 5 digits on an extremity, syndactyly, fusion of 
digits, and talipes commonly known as a club-foot (Figure 9). Furrowed soles are also 
seen in CLOVES (Figure 10C). Furrowing of the foot is due to fat deposits in the 
glabrous regions of the skin (Upton & Bloom, 2013).  
Hand deformities include spade-like asymmetric hands, ulnar deviation of the 
digits, macrodactyly (most prominently seen in the third digit), polydactyly and 
syndactyly (Figure 11B/C). Laxity of collateral ligaments specifically the thumb may be 
observed in patients as well (Upton & Bloom, 2013). Capillary malformations of the 
fingers are also frequently present (Figure 11A).  
Figure 9 Gigantic Lower Extremities. Infant has overgrowth of lower extremities with 
polydactyly of the right foot. Image taken from (Kurek et al., 2012) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	  	  
14 	  
14	  
Figure 10 Foot Deformities. A: Infant foot exhibiting macrodactyly of the third digit 
and syndactyly of the second-third toes. Image taken from (Klein et al., 2012) B: Sandal 
gap foot deformity. Image taken from (Upton and Bloom, 2013) C: Furrowed sole. Image 
taken from (Alomari, 2008). 
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Figure 11 Hand Deformities. A: Red blotches along epidermal layer of the skin indicate 
capillary malformation. Image taken from (Upton & Bloom 2013). B: Macrodactyly of 
third digit. Image taken from (Alomari, 2008). C: Asymmetric enlargement of third and 
fourth digits. Image taken from (Upton & Bloom 2013). 
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Cutaneous 
 
 Capillary malformations are present typically on truncal overgrowth masses and 
on the extremities in most patients (Upton & Bloom, 2013).  CMs are commonly referred 
to as port wine stains, such stains are of limited clinical significance. CLOVES patients 
may also present with epidermal nevi (Figure 12). Such lesions are caused by an 
overgrowth of skin cells leaving the epidermis of skin appearing a tan-dark brown color 
(Brandling 2010). Epidermal nevi are also of limited clinical significance and do not 
require intervention beyond basic dermatologic screening and examination of suspicious 
moles (Upton & Bloom, 2013).  
 
Figure 12 Epidermal Nevi. Dark patches on truncal region signify epidermal nevi. 
Image taken from (Alomari et al., 2011). 
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Miscellaneous findings  
 
 Findings outside of those included in the CLOVES acronym that may be present 
in patients typically affects the gastrointestinal (GI) system, orthopedic areas, genitalia 
and the viscera. The parts of the GI tract that are typically affected are the anorectum and 
the sigmoid colon. Thickening develops in each of these areas due to lymphatic and/or 
arteriovenous malformations. This can cause intestinal bleeding and patients will 
frequently report experiencing rectal bleeding (Sapp et al., 2007). Bleeding may be 
additionally caused by perianal lymphatic vesicles (Sapp et al., 2007). Chronic or acute 
bleeding of this type may lead to anemia and require blood transfusion.  
 The genitalia and urologic systems can additionally be affected. Scrotal 
lipomatous masses and VMs have been reported as two frequent anomalies in the 
genitalia. Renal agenesis or hypoplasia has also been frequently reported in CLOVES 
patients. Hypertrophy of the kidneys, renal cysts, and hydronephrosis are less frequent 
but are still a persistent finding (Upton & Bloom, 2013). In children such renal 
involvement may manifest as an increased risk for developing Wilms tumors. 
Malformations that affect the internal lining of the urinary bladder and hypertrophy of the 
bladder may lead to hematuria and incontinence.  
 Rarely it is reported that patients suffer from hepatosplenomegaly, (enlargement 
of the spleen and liver), inguinal hernias, dental abnormalities, and orthopedic problems. 
Orthopedic problems typically manifest as stiff joints, arthritis, and chondromalacia 
patellae, which means softening of the cartilage supporting the knee. 
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Distinction between CLOVES and KTS/PS 
 
Initial scientific reports have focused on delineating this syndrome and 
differentiating it from similar entities such as PS and KTS. In addition such reports have 
clarified various clinical aspects of these patients (Upton & Bloom, 2013). Several 
features differentiate CLOVES syndrome from PS and KTS. PS is a rare condition that is 
characterized by asymmetric overgrowth, deforming skeletal overgrowth, connective 
tissue nevi, epidermal nevi, elongated neck, vascular anomalies and mental retardation 
(Alomari, 2008). Vascular issues in PS tend to develop within the first month of birth, 
with a minute tendency to expand whereas in CLOVES such anomalies are congenital 
and lesions may magnify. Additionally lymphatic malformations (LM), paraspinal high 
flow lesions, and ectatic veins are seen in CLOVES but are absent from the various 
vascular anomalies in PS (Hoeger et al., 2004). The most defining clinical feature that 
differentiates the two conditions is overgrowth characteristics. Overgrowth can include 
the skeleton and adipose tissue. CLOVES patients possess overgrowths that are 
proportionate and progressive particularly involving the truncal area, whereas, in PS 
overgrowths are distorting and asymmetric (Sapp et al., 2007).  PS overgrowths can be 
further distinguished by its postnatal onset, while CLOVES patients are born with 
overgrowths and can be recognized prenatally (Sapp et al., 2007).   
The cardinal features of KTS include extensive slow-flow (venous, capillary 
lymphatic) vascular anomalies, and overgrowths that are predominately fatty, affecting 
the lower extremities and pelvis. While major defining features of CLOVES in 
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comparison to KTS include truncal lipomatous masses, high flow vascular 
malformations, and skeletal anomalies (Alomari et al., 2010).  
A distinctive gene mutation that results in CLOVES syndrome has recently been 
identified and confirmed as PIK3CA (Kurek et al., 2012). PIK3CA, is a protein that is 
apart of the PI3K-Akt pathway, PS and KTS both have proteins that are also mutated 
within this pathway which may explain some of the overlapping features that these 
syndromes posses. Importantly, identification of the PIK3CA mutation in CLOVES 
confirms that this syndrome is a separate disease from PS and KTS. Treatments should be 
tailored specifically to CLOVES patients to proficiently manage this syndrome.  
 
ETIOLOGY 
 
The gene mutation involved in CLOVES syndrome has been identified as a post-
zygotic spontaneous somatic activating mutation of the PIK3CA gene located on 
chromosome 3 (Kurek et al., 2012). Although mutations in PIK3CA differ slightly 
between patients, each point mutation has the same effect on the PI3K-Akt cell-signaling 
pathway (Figure 13). PI3K-Akt is a key intracellular molecular pathway that regulates 
cell division and growth. It is directly related to cell proliferation, cancer, and quiescence.   
In the normal pathway, PIK3CA is activated in response to tyrosine kinase ligand 
binding. (Tyrosine kinase receptors are involved in a variety of other general signaling 
mechanisms). Once activated PIK3CA proceeds to activate phosphoinositide-3-kinase 
(PI3K). PI3K activity leads to the conversion of phosphatidylinositol(3,4)-bisphosphate 
(PIP2) to phosphatidylinositol(3,4),5-triphosphate (PIP3), causing translocation and 
	  	  	  
20 	  
20	  
phosphorylation of PDK1 at the cell membrane. PDK1 then phosphorylates AKT 
initiating downstream cellular effects (Kurek et al., 2012).  
However, the mutation associated with CLOVES leads to mutant activation of PIK3CA, 
subsequent activation of PI3K and over phosphorylation of AKT, in the absence of 
external growth factor signaling. Triggering a cascade of events in early embryogenesis 
that can result in the phenotype of CLOVES syndrome (Kurek et al., 2012) (Figure 13).  
Proteus syndrome patients also have a mutant protein (AKT1), affected within 
this same pathway suggesting why there may be overlapping phenotypes with CLOVES 
patients (Figure 13). However, the non-overlapping phenotypes associated with the 
different mutations might reflect the stage of development at which the genetic alterations 
arose (Kurek et al., 2012). Similarly, Klippel-Trenaunay syndrome may also be caused by 
mutations in the PI3K-AKT pathway (Kurek et al., 2012). This has lead researchers to 
speculate that in the PIK3CA activating mutation, phenotypes within CLOVES patients 
may vary depending upon when the mutation arises during development (Kurek et al., 
2012). It is postulated that if the mutation arises early in development the same mutation 
will affect multiple cell lineages and will result in a more severe disease state in the 
patient (Kurek et al., 2012). Kurek et al., 2012 suggests that the presence of a large 
percentage of un-mutated cells within affected tissues (containing mutant PIK3CA cells), 
will respond to abnormal signals produced by cells carrying the PIK3CA mutation 
(innocent bystanders effect), further contributing to the syndromes malformations and 
overgrowths resulting in a more severe disease state.  
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In addition, Kurek et al., 2012 found PIK3CA missense mutations that are 
overexpressed in CLOVES patients have the capability to transform cells. Two out of six 
participants in the study of Kurek et al., 2012 had Wilms tumor in conjunction with 
CLOVES, suggesting that mutations in PIK3CA may have been a factor in the onset of 
Wilms tumor development. Researcher’s hypothesized that although PIK3CA missense 
mutations have the ability to transform cells there is not a high rate of cellular 
transformation seen in CLOVES patients, due to the low levels of endogenous PIK3CA 
missense mutations expressed in most cells. Explaining why only two out of six 
participants showed malignant cellular transformation.  
It is important to note that the same PIK3CA activating mutations identified in 
CLOVES syndrome are also expressed in several types of adult onset cancers such as 
brain, breast, bladder, lung and thyroid (Kurek et al., 2012). This cancer causing mutation 
is hypothesized to enhance the tumor’s growth or aggressiveness, rather than triggering 
transformation of cells as mentioned above (Kurek et al., 2012). In cancers the PI3k-Akt 
pathway is overactive reducing apoptosis (natural cell death) and promoting cell 
proliferation, thus contributing to the enhancement of tumor growth. This knowledge has 
prompted researchers to develop pharmacologic inhibitors against PIK3CA for the 
treatment of such tumors. These same inhibitors may eventually be used for therapeutic 
treatment of patients with CLOVES syndrome in the future (Kurek et al., 2012). Potential 
treatments would center on improving the lives of CLOVES patients since the disease is 
congenital and cannot be reversed.  
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Figure 13. PI3K-AKT Pathway. Yellow oval indicates the PI3K protein that is mutated 
causing CLOVES syndrome. Image taken from (Kurek et al., 2012).  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment strategies 
 Until therapeutic PIK3CA inhibitors exist, patients with CLOVES typically 
undergo many operative and diagnostic procedures over the course of their lives. 
Treatment is individualized because the disease as outlined above is a spectrum of 
problems that may manifest themselves to different degrees in each patient. To treat 
vascular anomalies sclerotherapy, embolization, and surgical resection are typically used. 
Resection is also used as treatment for lipomatous overgrowths. Sclerotherapy is a 
minimally invasive technique that works to reduce the size and pain associated with 
venous and lymphatic vascular malformations. During the procedure a sclerosant, a toxic 
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agent is injected into the malformation; causing the vessel to scar over, reduce in size and 
pain. Embolization, another minimally invasive technique is used to target arteriovenous 
malformations; this technique uses a catheter to move throughout the patient’s arteries to 
the problematic area. Once at the selected location, glue is injected to close the abnormal 
vessels. Both sclerotherapy and embolization have beneficial outcomes for CLOVES 
patients because each technique works to decrease the size of malformations, reducing 
the risk of pulmonary embolism and associated pain.  
Surgical debulking of a particular area is typically completed for patients who 
have vascular malformations accompanying lipomatous overgrowths. This procedure is a 
major invasive surgery that removes a portion of the overgrown tissue and malformations 
involved in CLOVES. Although this process involves multiple lengthy procedures, the 
quality of life of the patient is greatly improved after completion. Mobility of limb(s) 
may be regained and/or pain from the malformation can be reduced.  
Combined approaches of the 2-3 techniques above may be beneficial to selective patients. 
 Patients that have scoliosis are evaluated by spinal specialists who devise a plan 
to manage their spinal problems. In addition, many patients undergo secondary surgeries 
to treat complications and non-typical findings that may present. As mentioned earlier, a 
serious complication that is evident in CLOVES patients are pulmonary emboli. These 
clots are associated with the complex vascular anomalies that these patients possess and 
can lead to possible death. One significant goal of this study is to assess the risk of such 
complications, so that, appropriate assessment of risk can be performed and adequate 
precautions can be taken to prevent complications during surgical intervention.  
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SPECIFIC AIMS 
 
The first aim of this retrospective study is to systematically determine the adverse 
events associated with anesthesia and diagnostic or interventional procedures for patients 
with CLOVES syndrome. This was accomplished by retrospectively reviewing anesthetic 
and postoperative records of all CLOVES patients treated at Boston Children’s Hospital 
over the past nine years.  
Due to this study being preliminary we are heavily relying on the description of 
the population and specific adverse events from the current data collection. Previous 
anecdotal reports indicate that these patients are at risk for serious thromboembolic 
events in the perioperative period (Alomari et al., 2010) (Upton & Bloom, 2013).  
A second aim is to compare the current patient population to patients from 
previous studies that have been diagnosed with overlapping syndromes such as PS/KTS.  
This comparison will allow me to examine possible common origins and complications 
of the thromboembolic events in these patients.  
We predict that this study will identify common adverse events that complicate 
the perioperative period for CLOVES patients. Describing frequent complications that 
the current patient population suffers from will help physicians to devise better treatment 
options and preventative plans to minimize the occurrence of adverse events as a result of 
diagnostic and interventional procedures.  
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METHODS 
 
Patient selection 
  Our study cohort comprised patients in the Vascular Anomalies Center database 
with the diagnosis of CLOVES syndrome. Our primary group of interest was patients that 
were anesthetized at BCH since 2005 (the point at which anesthesia records are available 
in the electronic medical record). There were not any exclusion criteria for this study and 
all patients having CLOVES as a diagnosis were included.  IRB approval was obtained 
prior to patient selection.  
Study Treatments or exposures 
 
Due to the fact that this is a retrospective study, there are no research related 
interventions or treatments involved in the study. In addition we did not study any 
exposures, thus compliance was not required by the subjects or their designated 
parent/guardian(s).  
Data Collection 
 
Data were collected from BCH electronic medical records, using the Surginet 
interface. Only IRB approved staff members had access to the patient’s data. Names were 
replaced with numeric codes and the master code sheet was only accessible to the named 
investigators.  
Using the patient’s medical record number, we were able to access all of the 
anesthetic records and post-operative nursing and physician notes for each patient in the 
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study cohort.  After gaining subsequent access I recorded the patient age, gender, ASA 
level, estimated amount of blood loss (EBL), surgery status, MRI status, complication 
occurance(s), type of complication if any, and medical history. These data were recorded 
in a Microsoft Excel document on a password-protected computer.  
Data analysis  
Initial query of the Vascular Anomalies Center revealed that the patient 
population is extremely small, less than 40 patients were anesthetized at BCH and 
approximately100 patients overall with this diagnosis. Due to both of these factors, a 
descriptive study of the entire population at BCH was carried out with no statistical 
analysis beyond simple incidence and prevalence of certain characteristics. 	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RESULTS 
 A total of 38 CLOVES patients received diagnostic or interventional procedures 
at BCH for treatment of CLOVES syndrome. Out of these 38 patients 15 (or 39%) 
suffered from complications during the perioperative period. A total of 23 (or 61%) did 
not have complications, the data are summarized in Table 1.  We categorized an adverse 
event as an unanticipated problem that arose following a procedure, treatment, or illness 
during the perioperative period. Complications may arise directly from the disease or 
from independent causes. Multiple complications per patient were not accounted for in 
Table 1.  
Table 1: Total incidence of complications 
 
Since most patients received multiple anesthetics in our study population we also 
wanted to examine the rate of complications per individual anesthetic. Results in Table 2 
showed that out of the 175 anesthetics administered 17% were associated with 
complications. A total of 83% were not associated with complications.  
 
 
 
Total patients Total patients with 
complications 
Total patients with no 
complications 
38 15 (39%) 23 (61%) 
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Table 2: Total anesthetics associated with complications 
Total Anesthetics Total anesthetics with 
complications 
Total anesthetics with 
no complications 
175 30 (17%) 145 (83%) 
 
         Characteristics such as age and gender may play a role in the interpretation of total 
complication results. For this reason the patient population suffering from complications 
are broken down by these characteristics in Table 3. Infants were considered younger 
than (<) 1 years, children 1-12 years and adults greater than (>) 12 years of age. After 
basic statistical analysis between the three age groups and gender types, infant males 
significantly suffered from the highest number of adverse events. Within the children, 
males presented with more complications over females. In the adults, females suffered 
complications 80% of the time while 20% of males suffered from adverse events. 
Comparing data between the three age groups, the children and adult age groups suffered 
from more total complications than the infants.  
 Table 3: Total Complications by Age and Gender  
* If the same patient had multiple complications they were counted as individual 
complications 
Age Total 
complications 
Female Male 
Infant 5 0 5 (100%) 
Child 15 5 (33%) 10 (66%) 
Adult 10 8 (80%) 2 (20%) 
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Since anesthetics are administered to patients during operative and MRI 
procedures, data were compiled into Table 4 to illustrate the number of MRI versus 
surgical anesthetics that were received. It was found that anesthetics were administered 
significantly more in the surgical group (96%) in comparison to MRI (4%).  
Table 4: Patients undergoing MRI’s Versus Surgery  
 
Data were also grouped according to total patients undergoing surgery versus total 
deaths. It was found that 1% of patients died due to complications secondarily from 
surgery or underlying medical disorders that may have affected the  
perioperative period. 
Data were additionally organized to specifically highlight patients that suffered 
from complications. Table 5 displays in detail the number of complications that arose in 
each patient and the specific types of adverse events. Data in Table 5 were also graphed 
to determine the most frequent complications and trends that occurred in CLOVES 
patients (Figure14). It was found that PE/DVT, respiratory issues and hyper/hypotension 
were the most prevalent types of complications each with 6 occurrences. These results 
partially support our original hypothesis that the majority of complications that affect 
CLOVES patients will be due to clots or pulmonary embolus. The second most prevalent 
Total anesthetics Total patients receiving 
MRI’s  
Total patients undergoing 
surgery 
175 7 (4%) 168 (96%) 
	  	  	  
30 	  
30	  
complications were cardiac and bacterial infections both with 5 occurrences. Wound 
infections, post op fevers, and electrolyte abnormalities each subsequently had 4 
occurrences, being the third most common-set of complications.  
 Characteristics such as estimated blood loss (EBL) may play a role in the 
development of complication. For that reason patients in the complication cohort were 
grouped to determine if there was a correlation between significant blood loss and the 
occurrence of complications (Table 6). Significant blood loss is defined as a loss of blood 
that is at least half of the total blood volume of the patient. Total blood volume was 
calculated using this simple equation: 
 Patient’s weight (kg) x cc’s (age dependent) = Total Blood Volume. If a patient’s weight 
significantly varied between adverse events (AEs) then multiple weights were recorded to 
get an accurate calculation of blood volume (BV). Table 6 shows that 26% (4/15) of 
patients showed a positive association between an abundant EBL and the occurrence of 
complications.  
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Table 5: Descriptive List of Complications and Number of Complications Suffered 
Per Patient 
 
Patient Number of complications Type of complication 
1 1 1. Respiratory insufficiency 
 
4 1 1. Wound infection and 
dehiscence 
5 1 1. Hemiparesis 
6 5 1. Post-op fevers 2. 
Cellulitis, 3. Pseudomonas, 
4. Tachycardia, 5. 
persistant fluid drainage 
11 3 1. Hypertension 2. Wound 
pseudomonas  
3. Endotracheal tube 
plugged with subglottic 
granuloma  
14 1 1. Stridor  
16 4 1. Intraoperative 
hypotension due to PE 
2. Hypoatremic 
3. Swine flu 4. Deep 
Venous Thrombus (DVT) 
19 10 1. Severe hypotension (3x) 
2. Small PEs (3x) 
3.large IVC clot (2x) 
4. Pressure ulcer 
5. Wound 
infection/dehiscence 
6. Hypoatremia 
7.Psuedomonal sepsis (2x) 
8. Chronic hypocalcemia 
9. Hematuria/UTI 
10. Edematous legs 
 
20 2 1. Bradycardia 2. 
Respiratory distress  	  	  
 
	  	  	  
32 	  
32	  
 
Table 5: (continued) 
 
 
 
 
 
 
 
 
 
 
Patient Number of complications Type of complication 
21 5 1. Stridor 2. Hypothyriodism 
3. Mild hypoxia  
4. Respiratory distress 
5.Pulmonary edema 
22 4 1. Persistant bleeding from 
flank 2. Low Hematocrit  
3. Anemia 4. Seroma 
29 5 1. Stridor 2. Bacterial 
infection 3. High fevers (3x) 
4. Tachycardia 5. C-diff 
infection 	  	  
33 1 1. Cellulitis 
34 1 1. Wound dehiscence 
38 7 1. Hypotension 2. Respiratory 
alkalosis 3. Stridor  
4. Tachycardia 
5.Pseudomonas  
6. Hypokalemia 7. Arrhymias 
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Figure 14: Most prevalent complications. The “other” category represents the least 
frequent complications altogether. Ranging from anemia, hematuria/UTI, 
pulmonary edema, hypothyroidism, seroma, swine flu, to persistent bleeding from 
flank.  
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Table 6: Comparison of Significant Estimated Blood Loss with Complications 
 
Patient Weight (kg)  Total Blood 
Volume (mL) 
Estimated Blood 
Loss (mL) 
Significant 
Blood Loss 
Y/N 
1 66 4950 0 No 
4 52.8 3748 350 No 
5 21 1470 5 No 
6 21 1470 AE 1: 50 No 
AE 2: 0 No 
AE 3: 1800 Yes 
11 23 1610 AE 1: 210 No 
AE 2: 0 No 
14 20.6 1442 50 No 
16 59 4130 AE 1: 15 No 
AE 2: 900 No 
19 110 7700 AE 1:  1500 No 
60 4200 AE 2: 10 No 
AE 3: 50 No 
AE 4:10 No 
AE 5: 50 No 
AE 6: 2000 Yes 
AE 7: 0 No 
20 6.4 480 0 No 
21 12.85 899 120 No 
22 16.8 1176 0 No 
29 15.2 1064 AE 1: 0 No 
AE 2: 53 No 
AE 3: 6 No 
33 72.1 5400 3000  Yes 
34 13.1 910 1600 Yes 
38 8.8 660 AE 1: 0 No 
AE 2: 0 No 
AE 3: 0 No 
AE 4: 100 No 
*If weight significantly varied between adverse events (AEs) then multiple weights were 
recorded to get an accurate calculation of BV.  
*EBL’s per groups of adverse events (AEs) are recorded.  
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DISCUSSION 
  
After evaluating 38 CLOVES patients treated at BCH, we found multiple trends 
associated with the occurrence of complications. The literature suggests that CLOVES 
patients may suffer from various complications throughout the perioperative period. Our 
results in Table 1 reported a surprisingly high number of complications in this patient 
cohort in comparison to previous studies. Many of the patients in our sample may possess 
a more severe form of the disease. The increase in complications may reflect that any of 
the patients possessed more severe forms of the disease and that severe CLOVES 
requires additional intervention to effectively treat malformations/overgrowths. In 
addition, severe forms of CLOVES require additional procedures increasing the 
likelihood of complications. Furthermore as CLOVES patients age, this can exacerbate 
effects of the syndrome leading to impairment of healing capabilities. We believe that 
both factors are probable explanations for the increased percentage of complications 
noted in our data.  
Table 2 shows the rate of complication per individual anesthetic. Although 
anesthesia is more risky for CLOVES patients than the general population, it is still fairly 
safe. In the general population it is reported that the rate of adverse events for infants (0-
1), children (1-7), and adults (8-16) are as follows, 5.8%, 2.7%, and 2.6% per 1000 
anesthetics (Murat et al., 2004). We reported that 17% of total anesthetics were 
associated with complications and 83% were without complications. Out of the 17% only 
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1.2% were intraoperative complications and 87% were postoperative complications, 
indicating that very few of the complications were directly linked to anesthetics.  
 It is very surprising that PE/DVT were not more prevalent in our data because the 
first two descriptive studies of CLOVES, Sapp et al., 2007 and Alomari, 2008 reported 
that 1/7 (14%) and 2/18 (11%) of patients, respectively, suffered from significant 
thromboembolic events. This study shows that only 2/38 (5%) of patients experienced 
thromboembolic events. We suspect that this is a reflection of our success in recognizing 
that PE/DVT could be a severe issue and very aggressively treating these patients to 
prevent thromboembolic events.  
Respiratory issues included respiratory distress, insufficiency, alkalosis, and a 
clogged endotracheal tube. We noted that PE/DVT, respiratory issues, and 
hypo/hypertension all presented individually or together in patients. We believe this 
result was observed because when a clot forms in the pulmonary system this can cause 
the patient to display respiratory problems, such as distress or insufficiency and/or 
hypo/hypertension.  
 Cardiac issues included, brady/tachycardia and arrhythmias. Throughout the 
perioperative period the heart is under a great deal of stress, which may explain why 
cardiac complications were the second most prevalent adverse event. Infections are more 
prone to occur post surgery because incisions make it possible for bacteria to get past the 
protective skin layer. Other factors enhancing infection may include the temporary tubes 
inserted in the patient’s body allowing new routes for bacteria to travel as well as 
compromised immune surveillance associated with surgery.  
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  It is surprising that post operative fevers did not have a higher occurrence being 
that in general about 1/3rd of patients develop them and such fevers are known to present 
concurrently with infection. Electrolyte abnormalities are known to affect the blood 
coagulation system, it is surprising that these patients did not have more complications 
negating their coagulation systems due to the studies of Alomari, 2008 and Sapp et al., 
2007 both noting that coagulation homeostasis may be altered in CLOVES patients. 
However there was no direct correlation of altered coagulation homeostasis found in this 
study, likely due to the very high level of vigilance at BCH, with most CLOVES patients 
being followed by hematologists familiar with the condition throughout their 
perioperative stay.   
 No concrete correlations were found between significant blood loss and 
complication occurrence. Total blood volume per patient was calculated and EBL was 
compared, we found that for most patients EBL was not significant, making it hard to 
conclude if complications occurred more when there was substantial blood loss. Further 
research should be done in the future to continue to assess whether the number of 
complications is reduced if blood loss is minimized.  
As mentioned above two overgrowth syndromes, PS and KTS share many 
overlapping features with CLOVES. The latter is characterized by extensive capillary, 
lymphatic, and venous malformations in limbs, usually accompanied with soft tissue 
overgrowth (Bloom & Upton, 2013). The former is associated with vascular 
malformations, asymmetric skeletal overgrowth and dysregulated adipose overgrowth 
(Adams, 2011). Numerous reports document the increased incidence of coagulopathy in 
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both overgrowth syndromes (Adams, 2011) (Barbara & Wilson, 2011). Such fundamental 
research has made it possible to help elude the likely origin of the thromboembolic events 
that affects CLOVES patients and it’s comparative incidence.  
Adams, 2011, reports that after interventional treatment of vascular 
malformations, KTS patients may be at risk for developing disseminated intravascular 
coagulation (DIC), a condition in which the blood clotting factors have become 
overactive resulting in the formation of small blood clots. DIC may be further aggravated 
after a procedure by immobilization of the patient. Additionally, Adams, 2011 reports 
that thromboembolic events may occur spontaneously in both PS and KTS patients; 
however spontaneous occurrence is poorly explained. Lastly it is likely that 
thromboembolic events occur as a result of the enlarged veins that PS and KTS patients 
express. Dilated veins causes blood flow to become stagnant, and clot formation is more 
likely (Adams, 2011). We believe that each of these incidents offers an explanation for 
the thromboembolic events that CLOVES patients suffer from. However more research 
needs to be done on CLOVES patients to obtain significant findings.  
Chart inaccuracies may have been reported due to the study’s retrospective nature. 
Limitations of this study predominately stem from the small sample size reviewed. This 
may have caused a slight overestimation of percentages to be misrepresented in our 
results. Further studies and longitudinal follow-ups are needed to substantiate the findings 
in this study.  
In conclusion, our study was a retrospective chart review of anesthetic and post-
operative records for CLOVES patients. We systematically determined adverse events 
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associated with anesthesia and diagnostic or interventional procedures. Overall we report 
that the most common complications were PE/DVT, respiratory issues, and 
hypo/hypertension. In comparison to preliminary studies of Alomari, 2008 and Sapp et 
al., 2007, we report a lower occurrence of thromboembolic events in CLOVES patients. 
We hypothesize that this is because patients at BCH were treated aggressively with 
various prophylactic methods to help minimize the risk of such events. We recommend 
that early prophylactic anticoagulation methods are applied to future patients. 
Additionally, we recommend that CLOVES patients are followed by a hematologist and 
care team who are familiar with the condition throughout their stay at the hospital to 
reduce the risk of complications and optimize their care.  
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Rosie’s Place is a homeless shelter for women in the city of Boston. Prepared meals, 
served and visited with the residents, as well as cleaned up the dining room/kitchen. 
 
Physical Health Awareness Day-June 2013 (3 hours) 
Assisted the Psi Omega graduate chapter of Alpha Kappa Alpha Inc. by managing the 
children’s physical health awareness station. Showed kids that there are many ways to 
keep physically active that promotes good health through jump ropes and hula hoops, 
while testing their knowledge on healthy eating and physical activity categories.  
 
Beta Beta Beta Diabetes Bake Sale-March 2013 (4 hours) 
Aided in baking desserts and helped run bake sale table with other members of Tri-Beta 
to raise proceeds for diabetes awareness.  
 
Tutor at Turrentine Middle school-Burlington, NC January 2012-May 2013 
Each week I tutor one 7th grade math student to help her prepare for the standardized test 
that she along with the rest of her classmates must take at the end of the school year.  
 
Assistant event trainer for Attleboro Jaguars track team-Attleboro MA Summer 2011 
(12 hours) 
Assist children in long jump and javelin events at practice by giving them tips, and giving 
words of encouragement. At home track meets I also help run these two events for both 
girls and boys under the ages of 14.  
 
Apple street clean up-Burlington NC, September 2010-April 2013 (12 hours) 
Participated in the annual clean up of the Alpha Kappa Alpha Sorority Inc. adopted 
highway with chapter members.  
 
 
HONORS     
President’s List recipient (cumulative GPA of 3.7 or higher) May 2013 
	  	  	  
45 	  
45	  
Gamma Sigma Alpha Honor society (Greek students with a semester GPA of 3.5 or 
higher) April 2012 
            Dean’s list recipient (cumulative GPA of 3.5 or higher) May 2010, 2012, December 2011 
Tri beta Honor Society: (cumulative biology GPA 3.0 or higher) April 2011    
            Selected to participate in the Neuroscience research program at the Graduate College at the 
University of Illinois. May 2011-Conducted laboratory exercises in neuroscience and discussed 
Graduate/Medical School careers  
        Black Excellence Award recipient (cumulative GPA 3.2 or higher) January 2010-2013 
        Academic scholarship recipient for students in science given by The Middlesex Chapter of Links 
Inc. 2010, 2012 
Southern Conference Academic Honor roll recipient (All A’s and B’s along with a 3.2 GPA or 
above) 2009-2010, 2010-2011, 2011-2012, 2012-2013 
        
EXTRA -CURRICULAR ACTIVITIES 
Vice president and scholarship chair for the Omicron Epsilon chapter of Alpha Kappa 
Alpha Sorority Inc. May 2010-December 2012 
Varsity track and field team, Elon University, September 2009-May 2013 
Member of all-Freshman team in Southern Conference League April 2010  
Member of Lincoln pre-health society September 2009-2013 
Road race competitor- 2015-Present 
 
 
 
 
 
